Keeping Track: US FDA Approvals Of Saphnelo, Nexviazyme Balanced By CRLs For Rolontis, Treosulfan, Tenapanor

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

The FDA’s approval of two novel biologics, AstraZeneca PLC’s lupus therapy Saphnelo and Sanofi’s Pompe disease treatment Nexviazyme, was balanced by two complete response letters for novel agents.

In addition to the CRLs for Spectrum Pharmaceuticals Inc. and Hanmi’s chemotherapy induced-neutropenia treatment Rolontis and Medexus and

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers